This study explored the behavioural, neurochemical and molecular effects of D 9 -tetrahydrocannabinol (D 9 -THC) and WIN55,212-2, in two rat phenotypes, distinguished on the basis of their vertical activity upon exposure to a novel environment, as high responders (HR) and low responders (LR). Motor effects were assessed under habituated vs. non-habituated conditions. Dopaminergic activity and DARPP-32 phosphorylation were measured in the dorsal striatum, nucleus accumbens, prefrontal cortex and amygdala. These cannabinoids influenced motor activity in a biphasic manner, i.e. low doses stimulated, whereas high doses suppressed motor activity. Dopamine (DA) biosynthesis was increased in most brain regions studied following D 9 -THC administration mainly in HR rats, and low-dose WIN55,212-2 increased DA biosynthesis in HR rats only. Both high and low doses of D 9 -THC increased DARPP-32 phosphorylation in most brain regions studied in both phenotypes, an effect that was also observed following high-dose WIN55,212-2 administration only in the striatum. The present results provide further support for a key role of cannabinoids in the regulation of motoric responses and elements of dopaminergic neurotransmission and reveal their complex differential effects in distinct rat phenotypes, as seen with other drugs of abuse.
Introduction
Cannabinoids and the endocannabinoid system are implicated in the regulation of various physiological processes, including motivational and reward-related behaviour as well as affective and motoric responses (Iversen, 2003 ; Panagis et al. 2008 ; Solinas et al. 2008) . Most of the central nervous system (CNS) actions of exo-and endocannabinoids appear to be mainly mediated via CB 1 receptors (Gardner, 2005 ; Hashimotodani et al. 2007 ). D 9 -tetrahydrocannabinol (D 9 -THC), and synthetic CB 1 receptor agonists, such as WIN55,212-2, CP55,940 and HU-210, suppress motor activity, especially at high doses (Darmani, 2001 ; Giuliani et al. 2000 ; Jarbe et al. 2002 ; Schramm-Sapyta et al. 2007) . Behavioural studies have reported that the effects of marijuana, D 9 -THC, WIN55,212-2 and the endocannabinoid anandamide on locomotion follow a biphasic mode, characterized by motor activation at low doses and suppressed motor activity and catalepsy at high doses (Davis et al. 1974 ; Drews et al. 2005 ; Rodvelt et al. 2007 ; Sanudo-Pena et al. 2000 ; Sulcova et al. 1998) . However, there is a lack of detailed and consistent information on the specific doseresponse effects of cannabinoids on motor activity, primarily due to differences in experimental design and the disparity of results obtained.
Neurochemical studies assessing the biosynthesis, turnover rate and release of dopamine (DA) in forebrain regions that mediate motoric responses, have produced equivocal results, mainly due to methodological variances. In-vivo microdialysis studies have demonstrated increases in DA efflux in the nucleus accumbens (NAc), dorsolateral striatum and prefrontal cortex (PFC) with administration of D 9 -THC and WIN55,212-2 (Chen et al. 1990 (Chen et al. a, 1991 Malone & Taylor, 1999 ; Pistis et al. 2002 ; Tanda et al. 1999) . In contrast, Castaneda et al. (1991) reported no changes in DA levels in the NAc and striatum after D 9 -THC administration. Results obtained with ex-vivo methods follow the same pattern. In one study, no changes were found in tissue levels of DA and its metabolites or the DA turnover ratio in the striatum and limbic forebrain regions after administration of D 9 -THC in rats, while in another, increases in DA and its metabolite levels are observed in the same areas (Navarro et al. 1993a, b ; Rodriguez De Fonseca et al. 1992) . Although certain neurochemical responses after cannabinoid administration follow an unpredictable pattern, it is evident that specific molecular indices of dopaminergic neurotransmission are modulated in a variety of brain regions, including the NAc, striatum and PFC.
The DA-and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32) is highly expressed in several forebrain dopaminergic terminals, acting as a modulator of the cAMP pathway. DARPP-32 is implicated in the generation of motor responses produced by psychostimulants that modulate the cAMP/PKA pathway (Ferre, 1997 ; Lindskog et al. 2002 ; Svenningsson et al. 2002) . Previous studies have examined the effects of D 9 -THC and CP55,940 on DARPP-32 phosphorylation at the cAMP-dependent protein kinase site, Thr34, in the striatum and NAc of mice (Andersson et al. 2005 ; Borgkvist et al. 2008) . These studies proposed a link between stimulation of DARPP-32 phosphorylation and the motor suppressant effects of cannabinoids (Borgkvist & Fisone, 2007) . The effects of low, locomotor-stimulating doses of cannabinoids on DARPP-32 phosphorylation have not been reported.
Differentiated motor profiles of rats exposed to a novel environment have been associated with behavioural and neurobiological differences in response to psychostimulants (Piazza et al. 1989) . Particularly, animals that show a higher response to novelty (high responders, HR), exhibit a differentiated profile upon administration of psychostimulants (Antoniou et al. 2004 ; Cools et al. 1997 ; Piazza et al. 1990 ), compared to those showing a lower response (low responders, LR). Apparently, no study has focused on individual differences in response to cannabinoids.
Our aim was to investigate the behavioural, neurochemical and molecular effects of D 9 -THC and WIN55,212-2, two CB 1 receptor agonists with distinct pharmacological profiles in, for example cannabinoid receptor selectivity, potency and efficacy in two rat phenotypes previously differentiated as HR or LR, according to their response to a novel environment. Initially, a wide range of doses of D 9 -THC and WIN55,212-2 was used to investigate their stimulatory or suppressant effects on motor activity in a nonhabituated experimental setting. Subsequently, two doses were selected that better reflect the biphasic motor profile induced by the cannabinoids in order to further study their effects on locomotor activity in HR and LR animals that were habituated to the testing environment. Neurochemical and molecular indices of dopaminergic neurotransmission in discrete brain regions, which play a major role in the neurobiological mechanisms of addiction and in the psychotropic effects of cannabinoids, were also examined following the two selected doses of cannabinoids. Particularly, tissue levels of DA and its metabolites and the phosphorylation of DARPP-32 at Thr34 in the dorsal striatum, NAc, PFC and amygdala were assessed following these doses of D 9 -THC and WIN55,212-2, in HR and LR animals.
Methods

Animals
Male Sprague-Dawley rats (inbred at the Animal Center of the University of Ioannina), aged 80-90 d and weighing 250-300 g were used. The animals were group-housed in plastic cages (42.5r26.6r15.5 cm) with food and water available ad libitum and under a controlled 12-h light/dark cycle (lights on 07:00 hours) and temperature (21¡1 xC) conditions. All experiments were reviewed and approved by the local ethics committee and carried out in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals (NIH Publication No. 80-23 ; revised 1996) .
Behavioural analysis
Classification of rats
Animals used in the present study were classified as HR and LR according to their vertical counts in an activity chamber (Antoniou et al. 2004 (Antoniou et al. , 2008 . Vertical activity (rearing) as one of the main behavioural responses to novelty reflects aspects of exploration, arousal, locomotion and emotionality and, apart from locomotion, is a valuable variable used for the phenotypic classification of rats (Thiel et al. 1999) . The animals were accustomed to the experimental room for 40 min prior to the experiment. They were then introduced into a transparent open activity box (40r40r40 cm) and their behaviour was recorded for a 15-min period with computerized activity monitoring (ENV515, Activity Monitor, Version 5, Med Associates, USA). The rats were ranked using frequency of vertical counts (rearing) and the animals above the median (50 counts) were designated as HR, while the rest were classified as LR. After assignment to HR/LR groups, the animals were left undisturbed for at least 20 d and then subjected to subsequent behavioural, neurochemical or molecular experimentation. This period was chosen to avoid the risk that reexposure to the testing environment might influence behaviour, especially in the non-habituated rats. Groups of 16-20 rats per drug dose matched for HR and LR were used for behavioural and neurochemical tests, while groups of 8-10 rats per drug dose were used for molecular analysis, respectively.
Non-habituated and habituated motor activity
All animals were again accustomed to the experimental room for 40 min prior to the experiment. The following variables were registered : ambulatory distance, time and counts, vertical counts and resting time. Vertical counts represented vertical activity and ambulatory distance was used as index of horizontal activity.
A subset (n=106) of rats was used for the nonhabituated motor activity experiments. Subsequently, rats were injected intraperitoneally (i.p.) with vehicle, D 9 -THC (0.375, 0.75, 1.5, 3 mg/kg) or WIN55,212-2 (0.03, 0.1, 0.3, 1 mg/kg) in their home cages and 10 min post-treatment they were placed in the testing apparatus and motor activity was recorded for 1 h. Another subset of rats (n=70) was used for habituated motor activity experiments. The rats were habituated for 20 min, and they were then injected with vehicle, D 9 -THC (0.75, 3 mg/kg) or WIN55,212-2 (0.1, 1 mg/kg) and immediately returned to the activity box. Motor activity was recorded for 1 h, starting 10 min posttreatment. Low doses were chosen based on their possible stimulatory role in motor activity, which as expected was masked in non-habituated animals, whereas the high doses were selected based on their suppressant actions on locomotion. These two doses were also selected for the neurochemical and molecular experiments (see below), as representative of motor-stimulating and motor-suppressant doses of cannabinoid agonists.
Neurochemical/molecular analyses
Tissue preparation
Two subsets of rats were used for neurochemical (n=72) and molecular analyses (n=42). One hour after injection (i.p.) with vehicle, D 9 -THC (0.75, 3 mg/ kg) or WIN55,212-2 (0.1, 1 mg/kg), all groups of rats were sacrificed by decapitation, their brains were rapidly removed and the following discrete regions were dissected on ice : amygdala, PFC, dorsal striatum and NAc.
Neurochemical analysis
Once the tissue was weighed, each sample was homogenized and deproteinized and analysed for DA and its metabolites homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC) using reversephase ion-pair chromatography on a high-performance liquid chromatography system with electrochemical detection (HPLC-ED, BAS-LC4B) (Antoniou et al. 2008) . Finally, the turnover ratios DOPAC/DA and HVA/DA were calculated and used as indices of DA release, reuptake and metabolism to DOPAC and HVA (Commissiong, 1985) . The ratios of DA/DOPAC and DA/HVA as well as the sums of DA+DOPAC and DA+HVA, were also estimated and used as indices of DA biosynthesis (Hitzemann et al. 1982 ; Miura et al. 2002 ; Tavares et al. 2003) .
Molecular analysis
The dissected regions from each rat were homogenized by sonication in an ice-cold buffer [50 mM Hepes (pH 7.4), 0.5 % NP40, 10 % glycerol, 137 mM NaCl, 10 mM NaF, 100 mM DTT, protease inhibitor cocktail, phosphatase inhibitor cocktail 1 or 2]. Samples containing equal amount of protein (50 mg) were mixed with the appropriate amount of 0.5 M Tris-HCl, sample buffer and were loaded in a 10 % acryl/bisacrylamide. After electrophoresis, the gels were electrically transferred onto a Protran 1 nitrocellulose membrane (Schleischer & Schuell, Germany) . Incubation with a polyclonal anti-phosphoDARPP-32 (Thr34) (1 : 500, Cell Signaling, USA) and anti-DARPP-32 antibody (1 : 500, Cell Signaling) was performed overnight at 4 xC. Membranes were then incubated with HRP anti-rabbit, anti-biotin secondary antibody, 1 : 1500 (Chemicon International Inc., USA) for 1 h at 4 xC. Immunoreactive bands were visualized by enhanced chemiluminescence (ECL) detection solutions and ECL Hyperfilm exposure (Amersham Biosciences Corp., USA). Quantification of immunoreactive bands was performed using computer-assisted densitometry (ScionImage, USA). The optical density of each band (phosphor-Thr34-DARPP-32) was divided by that of its respective total content of the DARPP-32 band to normalize the band intensity. These ratios were then statistically normalized with the respective values of the vehicle-treated rats.
Drugs WIN55,212-2 (Tocris Bioscience, UK) was dissolved in a vehicle solution that consisted of 5 % dimethylsulfoxide, 5 % cremophor EL and 90 % NaCl (0.9 %). D 9 -THC ethanol solution (30 mg/ml) (Sigma-Aldrich Chemie GmbH, Germany) was stored at x20 xC and appropriate amounts were sublimated/withdrawn and dissolved in the vehicle solution.
Statistical analysis
Two-way analyses of variance (ANOVA) with treatment and phenotype as factors were performed for all available data. Separate one-way ANOVAs were conducted for the analysis of treatment effect per phenotype or for the assessment of differences between the two phenotypes per dose. Subsequent multiple-range tests were used for the evaluation of specific group comparisons. All figures presented here display mean values+S.E.M. A probability of pf0.05 was considered significant.
Results
Behavioural analysis
Vehicle-treated rats
Higher vertical counts were found in HR compared to LR rats (F 1,19 =3.55, p=0.05) in non-habituated animals indicating consistent individual differences between the two phenotypes (Figs 1 a, 2a). As expected, there was no significant difference between the two phenotypes in habituated rats, indicating lack of this differentiation between the two phenotypes after the habituation period (Figs 1 b, 2b).
-THC-treated rats Two-way ANOVA revealed a significant D 9 -THC treatment effect. Reduced ambulatory distance and vertical counts were observed with high doses of D 9 -THC compared to vehicle (F 4,63 =4.02, p=0.006 ; F 4,63 = 5.23, p=0.001, respectively) ( Fig. 1 a) . HR rats exhibited increased ambulatory distance and higher vertical counts (F 1,63 =6.46, p=0.0014 ; F 1,63 =20.6, p= 0.001, respectively) compared to LR rats. Separate analyses per phenotype revealed that the D 9 -THCinduced decrease in vertical counts was seen in both HR and LR animals (F 4,30 =3.17, p=0.031 ; F 4,35 =4.10, p=0.009, respectively) ( Fig. 1 a) . The decreased ambulatory distance was observed only in HR rats (F 4,35 = 3.18, p=0.026) (Fig. 1 a) . Additional analyses per dose revealed that higher ambulatory distance and vertical counts were displayed in HR, compared to LR rats, and this effect was most prominent with 0.75 mg/kg D 9 -THC (F 1,12 =5.79, p=0.032 ; F 1,14 =12.7, p=0.006, respectively) ( Fig. 1 a) .
Based on these findings, two doses of D 9 -THC (0.75, 3 mg/kg) that reflect its biphasic effects on motor activity were selected for further experiments in habituated rats. Two-way ANOVA revealed an increase in the ambulatory distance in habituated rats treated with the low dose of D 9 -THC compared to vehicle (F 2,35 =3.75, p=0.037). This analysis also revealed that HR rats displayed increased ambulatory distance compared to LR rats (F 2,33 =3.70, p=0.044). Separate one-way ANOVAs per phenotype revealed that the D 9 -THC-induced increase of ambulatory distance and vertical counts was exhibited only in HR habituated rats (F 2,19 =6.7, p=0.037 ; F 2,19 =6.8, p=0.038, respectively) (Fig. 1b) .
WIN55,212-2-treated rats
Two-way ANOVA revealed a decrease in ambulatory and vertical activity (F 4,79 =4.57, p=0.003 ; F 4,79 =3.84, p=0.007, respectively) with the high doses of WIN55,212-2 compared to vehicle (Fig. 2a) . This (Fig. 2 a) . Analyses per treatment revealed that HR rats exhibited higher vertical/ambulatory activity compared to LR rats following 0.1 mg/kg WIN55,212-2 (F 1,20 =3.78, p=0.005 ; F 1,20 =7.32, p=0.014, respectively) (Fig. 2 a) .
The two representative doses of WIN55,212-2 (0.1, 1 mg/kg) were chosen for further experiments in habituated animals. According to the two-way ANOVA, 0.1 mg/kg WIN55,212-2 increased ambulatory distance and vertical counts in habituated rats (F 2,34 =10.71, p=0.002 ; F 2,34 =11.7, p=0.002, respectively). Increased ambulatory distance and enhanced vertical counts were observed in both HR and LR habituated rats following the low dose of WIN55,212-2 (F 2,20 =5.8, p=0.022 ; F 2,19 =7.3, p=0.007 ; F 2,18 =8.1, p=0.006 ; F 2,19 =4.17, p=0.042, respectively) ( Fig. 2 b) . Although there was an increase in ambulatory distance in HR compared to LR rats following WIN55,212-2 (0.1 mg/kg), this increase did not reach statistical significance (Fig. 2 b) .
Neurochemical analysis
Basal dopaminergic activity in HR and LR rats
With regard to basal levels of dopaminergic activity in the striatum, HR rats exhibited an increased turnover ratio (HVA/DA) and a corresponding decreased biosynthesis ratio (DA/HVA) compared to LR rats (F 1,14 = 6.473, p=0.024 ; F 1,14 =4.654, p=0.05, respectively) (Tables 1 a, 3a). HR rats presented higher basal DOPAC levels compared to LR rats in the amygdala (F 1,15 =3.349, p=0.05) (Tables 2b, 4b ).
Dopaminergic activity in D
9
-THC-treated rats
In the dorsal striatum, a two-way ANOVA revealed a statistically significant phenotype effect for the DA turnover ratio (DOPAC/DA) and the DA synthesis ratio (DA/DOPAC) (F 1,26 =4.35, p=0.05 ; F 1,26 =5.741, p=0.026, respectively) and a statistically significant treatment effect for sum of DA (HVA+DA), turnover ratio (HVA/DA) and synthesis ratio (DA/HVA) (F 2,26 =3.64, p=0.045 ; F 2,26 =5.14, p=0.016 ; F 2,26 =6.61, p=0.006, respectively). In particular, the sum of DA was increased upon administration of 0.75 mg/kg D 9 -THC, and upon 3 mg/kg D 9 -THC administration the DA turnover ratio was increased and the synthesis ratio decreased analogously. This increased sum (HVA+DA) was observed only in HR rats (F 2,15 =4.93, p=0.025). The increase in the turnover ratio (HVA/ DA) and the corresponding decrease in the biosynthesis ratio (DA/HVA) observed with the high dose of D 9 -THC was attributable to LR rats (F 2,13 =4.54, p= 0.036 ; F 2,13 =6.28, p=0.015, respectively) (Table 1 a) .
Regarding the NAc, a two-way ANOVA revealed an increase in the HVA turnover ratio (HVA/DA) after the high dose of D 9 -THC (F 2,26 =4.286, p=0.028). Analyses per phenotype revealed that this increased turnover ratio was observed in LR rats (F 2,13 =4.715, p=0.036) (Table 1a) . Notably, an increased biosynthesis ratio (DA/DOPAC) in the NAc following both doses of D 9 -THC was found only in HR rats (F 2,13 = 5.71, p=0.018) (Table 1 b) .
In the PFC, a two-way ANOVA revealed an increase in DOPAC+DA sum, which reflects increased biosynthesis, following D 9 -THC administration (F 2,29 = 10.615, p=0.001). This observed increase was significant for both phenotypes (F 2,13 =5.132, p=0.027, F 2,15 =5.947, p=0.015 ; HR and LR, respectively), following the low dose of D 9 -THC (Table 2 a). In the amygdala, a two-way ANOVA revealed a decrease in the DA turnover ratio (DOPAC/DA) accompanied by an increase in the synthesis ratio (DA/ DOPAC) following D 9 -THC (F 2,28 =4.61, p=0.021 ; F 2,28 =8.451, p=0.002, respectively). This increase in the biosynthesis ratio was observed in both phenotypes, upon administration of the high dose of D 9 -THC (F 2,15 =5.125, p=0.023 ; F 2,15 =4.44, p=0.039, respectively). LR rats showed an increase in the sums DOPAC+DA and HVA+DA after the low dose of D 9 -THC (F 2,12 =6.23, p=0.017 ; F 2,12 =5.79, p=0.021, respectively) (Table 2 b).
Dopaminergic activity in WIN55,212-2-treated rats
In the striatum, a two-way ANOVA revealed a treatment effect for DOPAC+DA and HVA+DA sums (F 2,36= 7.64, p=0.002 ; F 2,36 =8.15, p=0.001, respectively). In particular, an increased sum of DA was observed following WIN55,212-2. The increased sums after the low dose of WIN55,212-2 were observed only in HR rats (F 2,16 =5.942, p=0.014 ; F 2,19 =8.97, p=0.002, respectively) (Table 2 a). Further analysis (not shown) revealed that these results held when DA tissue levels were also examined. A corresponding decrease in the turnover ratio (HVA/DA) was observed following both doses only in HR rats (F 2,19 =6.185, p=0.010) (Table 3 a) .
Regarding the NAc, a two-way ANOVA revealed an increase in the DA/DOPAC ratio (an index of DA synthesis ratio) following the low dose of WIN55,212-2 (F 2,31 =4.101, p=0.028). This increased biosynthesis ratio was probably due to HR rats (F 2,13 =5.439, p= 0.023) (Table 3 b) .
In the PFC, a two-way ANOVA revealed an increase in DA synthesis (DA/DOPAC) after administration of 0.1 mg/kg WIN55,212-2 (F 2,38 =5.4, p=0.01) (Table 2 b). This increase (F 2,17 =7.921, p=0.004) was only observed in HR rats (Table 4 a).
In the amygdala, a two-way ANOVA revealed an increase in DOPAC+DA and HVA+DA sums and the DA/DOPAC ratio following administration of WIN55,212-2 (F 2,41 =3.786, p=0.007 ; F 2,41 =3.055, p=0.05 ; F 2,41 =3.70, p=0.035, respectively). This increased ratio and a corresponding decreased turnover ratio (DOPAC/DA) were observed following the low dose of WIN55,212-2 (F 2,41 =3.9, p=0.028 ; F 2,41 =5.5, p=0.008, respectively) in HR rats (Table 4 b).
Molecular analysis
Basal levels of DARPP-32 phosphorylation in HR and LR rats
Interestingly, there were no significant differences in the ratio phosphor-Thr34-DARPP-32/total DARPP-32 in all brain regions tested, between HR and LR rats in response to vehicle (Figs 3, 4) .
DARPP-32 phosphorylation in D
9
In the striatum, a two-way ANOVA revealed a phenotype effect and a phenotypertreatment interaction for the phosphorylated DARPP-32 levels (F 1,23 =11.53, p=0.004 ; F 2,23 =3.7, p=0.05, respectively). HR displayed higher phosphorylated DARPP-32 levels compared to LR rats. Subsequent per phenotype one-way ANOVAs showed an increase in the phosphorylated DARPP-32 levels (F 2,11 =3.4, p=0.05), especially with the high dose of D 9 -THC, only in HR rats (Fig. 3) . Further analysis showed increased phosphorylated DARPP-32 levels in HR compared to LR rats, following D 9 -THC administration (F 1,7 =6.5, p=0.05 ; F 1,7 = 10.99, p=0.016) (Fig. 3) .
Regarding the NAc, a two-way ANOVA revealed an increase in phosphorylated DARPP-32 levels (F 2,26 =6.17, p=0.008) following both doses of D 9 -THC compared to vehicle. Further one-way ANOVAs showed an increase in the phosphorylated DARPP-32 levels for both phenotypes (F 2,12 =4.3, p=0.05 ; F 2,14 = 3.4, p=0.04) following D 9 -THC (Fig. 3 ).
In the PFC, a two-way ANOVA revealed enhanced phosphorylated DARPP-32 levels with the low dose compared to the high dose of D 9 -THC and vehicle (F 1,23 =7.37, p=0.004). Further one-way ANOVAs showed that this effect was observed in both HR and LR rats (F 2,12 =4.55, p=0.05 ; F 2,12 =4.35, p=0.05, respectively) (Fig. 3) .
In the amygdala, a two-way ANOVA revealed a reduction in phosphorylated DARPP-32 protein levels at the low dose compared to the high dose of D 9 -THC (F 2,23 =4.35, p=0.029). Subsequent per phenotype oneway ANOVAs showed that this reduction was observed in LR rats only (F 2,12 =11.07, p=0.003) (Fig. 3) .
DARPP-32 phosphorylation in WIN55,212-2-treated rats
Phosphorylated DARPP-32 protein levels in the striatum were increased by the high WIN55,212-2 dose (Fig. 4) . In the NAc, a two-way ANOVA also revealed an increase in phosphorylated DARPP-32 levels (F 2,32 = 9.49, p=0.001) at the high dose of WIN55,212-2 compared to the low dose and vehicle. Further one-way ANOVAs showed that this increase was observed in both phenotypes (F 2,17 =7.2, p=0.006 ; F 2,14 =5.2, p=0.024) (Fig. 4) .
Phosphorylated DARPP-32 protein levels in the PFC were higher in HR compared to LR rats following WIN55,212-2 (F 1,31 =7.79, p=0.01). The same two-way ANOVA also revealed a significant interaction (F 2,31 = 3.74, p=0.037). Further one-way ANOVAs showed a decrease in the phosphorylated DARPP-32 levels in the PFC only in LR rats (F 2,12 =7.7, p=0.009) after the high WIN55,212-2 dose (Fig. 4) . There was no statistically significant treatment or phenotype effect for phosphorylated DARPP-32 levels in the amygdala (Fig. 4) .
Discussion
The present results show that D 9 -THC and WIN55,212-2 influenced motor activity in a biphasic manner, depending on whether the animals were tested under habituated or non-habituated conditions. Low doses of both cannabinoids increased motor activity in a familiar environment, whereas high doses decreased motor activity in an unfamiliar environment (Table 5) . These dual behavioural responses were better defined in HR compared to LR rats (Table 5) . Neurochemical indices related to DA biosynthesis were increased in most of the brain regions studied following a low and high dose of D 9 -THC mainly in HR rats, and a low dose of WIN55,212-2 increased DA biosynthesis in HR rats (Table 5 ). Both doses of D 9 -THC increased DARPP-32 phosphorylation in most brain regions studied in both HR and LR rats, while a high dose of WIN55,212-2 increased DARPP-32 phosporylation in certain brain regions in both phenotypes (Table 5) .
Specifically, low doses of D 9 -THC and WIN55,212-2 increased, whereas high doses of these cannabinoids decreased, ambulatory and vertical activity. Interestingly, there is a dose-dependent interaction between novelty-induced arousal, behavioural habituation and cannabinoids. Exposure to a novel environment reflects a complex phenomenon characterized by motor activity, arousal, emotionality and general excitability (Cerbone & Sadile, 1994) . Based on our findings in non-habituated and habituated rats, respectively, it could be suggested that high doses of cannabinoids reduced the expression of novelty-induced behaviour, while low doses disrupt behavioural habituation resulting in increases in motor and exploratory activity, as well. These results are in agreement with previous data showing sedative effects and catalepsy following high doses of D 9 -THC and WIN55,212-2 (Jarbe et al. 2002 ; Lichtman et al. 2001 ; Sanudo-Pena et al. 2000 ; Schramm-Sapyta et al. 2007 ). Other studies with WIN55,212-2, do not report a decrease in motor activity at higher doses (Drews et al. 2005 ; Pandolfo et al. 2007 ; Przegalinski et al. 2005 ; Rodvelt et al. 2007) . Sanudo-Pena et al. (2000) do not detect a decrease in horizontal activity following 3 mg/kg D 9 -THC. Corroborating previous data based on the effects of various cannabinoid receptor agonists (Drews et al. 2005 ; Giuliani et al. 2000 ; Sanudo-Pena et al. 2000) , the present findings clearly demonstrate a stimulatory effect on motor activity after 0.75 mg/kg D 9 -THC and 0.1 mg/kg WIN55,212-2. A higher dose (0.6 mg/kg) of WIN55,212-2 has been shown to produce similar effects (Drews et al. 2005) , while other authors do not detect any stimulatory effect on motor activity following low doses of D 9 -THC or WIN55,212-2 (Jarbe et al. 2002 ; Pandolfo et al. 2007 ; Rodvelt et al. 2007) . The biphasic pattern in motor activity was mainly observed in HR rats. Several studies have focused on behavioural differences induced by psychostimulants between groups of rats previously differentiated according to their response to novelty (Antoniou et al. 2004 (Antoniou et al. , 2008 Cools et al. 1997 ; Piazza et al. 1990 ). These effects were not attributable to different sensitivity to reward-related variables (Antoniou et al. 2004 ; Wise, 1996) . It seems that differences in the complex phenomenon of novelty behaviour might reflect a qualitatively different behavioural organization that could be responsible for different responding to psychostimulant administration, or generally for differences in the reaction to specific test conditions (Antoniou et al. 2004) . The disparity in the results obtained with specific doses of cannabinoids that differentially affect motor activity could be attributable to individual differences, rat strain, the interval after drug administration, the registration period or, especially, habituation (or lack) of the experimental animals to the activity chambers. Considering, in general, that a decrease in motor activity is better detected in non-habituated animals, while an increase in motor activity is better distinguished in habituated animals -trends supported by our findings -we conclude that D 9 -THC and WIN55,212-2 exerted a biphasic action on motor activity and these effects were more prominent in HR rats.
The neurochemical data show that dopaminergic activity was modulated in a similar, but regiondependent manner following both cannabinoids. In particular, increased synthesis of DA, as reflected by either the sum of DA and its metabolites (Tavares et al. 2003) or the ratio of DA/DOPAC and DA/HVA (Hitzemann et al. 1982 ; Miura et al. 2002) , was observed in all brain regions studied following D 9 -THC administration. A consistent pattern was also observed in response to WIN55,212-2, especially at the low dose. These findings are in agreement with in-vivo studies that have shown increases in extracellular DA release in the NAc after D 9 -THC, an effect which was found to be rat strain-dependent (Chen et al. 1990b ; Ng Cheong Ton et al. 1988) . Other studies have elegantly demonstrated a dose-and area-dependent DA increase in the shell and not the core of the NAc upon intravenous administration of D 9 -THC and WIN55,212-2 ( Lecca et al. 2006 ; Tanda et al. 1997) , a phenomenon which also applies to other drugs of abuse (Di Chiara et al. 2004 ; Pontieri et al. 1995 Pontieri et al. , 1996 . Dose-dependent increases in DA efflux have also been observed in the striatum and the PFC following intravenous or parenteral administration of D 9 -THC (Chen et al. 1990b ; Malone & Taylor, 1999 ; Pistis et al. 2002) . Ex-vivo neurochemical approaches displayed a rather unpredictable pattern. No changes were seen in DA and DOPAC levels or the turnover ratio of DOPAC/DA in the striatum and limbic forebrain after D 9 -THC administration in rats and increases in DA and DOPAC tissue levels were also observed in the same areas (Navarro et al. 1993a, b ; Rodriguez De Fonseca et al. 1992 ). In the amygdala, an increase in DA content was observed after D 9 -THC administration (Hernandez-Tristan et al. 2000) . According to our data, D 9 -THC stimulated DA biosynthesis and this regiondependent effect was more prominent in HR rats. Similarly to the effect of D 9 -THC, this increase was also detected in all brain regions studied following the low dose of WIN55,212-2 only in HR rats. These findings are consistent with results obtained by Carey (1986) , # p<0.05 : HR vs. LR rats. Piazza et al. (1990) , Cools et al. (1997) and Kabbaj et al. (2001) , which showed that HR rats exhibit higher dopaminergic activity, compared to LR rats in response to cocaine and d-amphetamine. Based on the aforementioned studies and our findings, it appears that systemic administration of D 9 -THC and WIN55,212-2 stimulate dopaminergic indices mainly associated with DA biosynthesis and predominantly in HR rats. A number of studies have tried to elucidate the mechanism of action of cannabinoids in these DArelated responses (Cheer et al. 2004 ; Gardner, 2005 ; Pierce & Kumaresan, 2006 ; Rodvelt et al. 2007 ; Tanda & Goldberg, 2003) . Collectively, these studies suggest a certain effect of cannabinoids on dopaminergic neurons and terminals along with another modulatory role on the DA transporter. The presence of CB 1 receptors in dopaminergic terminals and subsequent presynaptic modulation of DA release has been extensively proposed (e.g. Degroot & Nomikos, 2007 ; O'Neill et al. 2009 ). Perhaps cannabinoids affect dopaminergic status in a specific manner in which methodological and individual aspects seem to play a critical role. Still, it needs to be underlined that the detected changes in dopaminergic activity in response to the studied cannabinoids do not follow a biphasic pattern of response in a dose continuum, as that observed in motor activity. This suggests that other components of the dopaminergic system such as recruitment of both D 1 and D 2 receptors or altogether other neurotransmitter systems are specifically engaged in the motoric dichotomy found in response to the studied CB 1 receptor agonists.
Systemic administration of D 9 -THC and WIN55,212-2 modulated DARPP-32 phosphorylation at Thr34 in a dose-and region-dependent manner. D 9 -THC enhanced phosphorylation of DARPP-32 at Thr34 in all regions studied with the exception of the amygdala. Stimulation of DARPP-32 phosphorylation was also detected after the high dose of WIN55,212-2 in 
THC, Tetrahydrocannabinol ; DA, dopamine ; DOPAC, 3,4-dihydroxyphenylacetic acid ; HVA, homovanillic acid ; h, habituated ; non-h, non-habituated.
‹ , ›, Statistically significant increase or decrease in any measure of motor activity, dopaminergic activity and DARPP-32 phosphorylation compared to vehicle.
